A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

ProRx Pharma, the wellness and longevity 503B outsourcing facility, has announced the expansion of its operations to help meet the demand for critical medications?now and into the future with a full ...

The lawsuit, filed by the Outsourcing Facilities Association , FarmaKeio Custom Compounding and North American Custom Laboratories in the U.S. District Court for the Northern District of Texas, argues ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

European stocks are soaring as American markets stay choppy. With more European military spending on the horizon, defense ...